| Literature DB >> 29742621 |
Bin Lian1,2,3, Jinjun Xia1,2,3, Xun Yang1,4,2, Chanjuan Zhou5,2,3, Xue Gong1,4,2, Siwen Gui1,2, Qiang Mao1,2, Ling Wang1,2, Pengfei Li1,4,2, Cheng Huang1,4,2, Xunzhong Qi1,4,2, Peng Xie5,1,4,2.
Abstract
In the present study, we used a gas chromatography-mass spectrometry-based metabolomics method to evaluate the effects of ketamine on mice hippocampi. Multivariate statistical analysis and ingenuity pathway analysis were then used to identify and explore the potential mechanisms and biofunction of ketamine. Compared with the control (CON) group, 14 differential metabolites that involved amino acid metabolism, energy metabolism, and oxidative stress metabolism were identified. After combination with 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) administration, six of the 14 metabolites remained significantly differentially expressed between the ketamine (KET) and KET+NBQX groups, including glycine, alanine, glutamine, aspartic acid, myoinositol, and ascorbate, whereas no difference was found in the levels of the other eight metabolites between the KET and KET+NBQX groups, including phosphate, 4-aminobutyric acid, urea, creatine, L-malic acid, galactinol, inosine, and aminomalonic. Our findings indicate that ketamine exerts antidepressant effects through an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid inhibition-dependent mechanism and a mechanism not affected by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid inhibition. Which provides further insight into the therapeutic mechanisms of ketamine in the hippocampus.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29742621 DOI: 10.1097/WNR.0000000000001020
Source DB: PubMed Journal: Neuroreport ISSN: 0959-4965 Impact factor: 1.837